Chairs: Jonas Bergh (Sweden), C. Kent Osborne (USA)
Intratumoral heterogeneity and subclonal diversification of early breast cancer
Lucy R. Yates, UK
Clonal evolution and clonal selection induced by therapy in the adjuvant and neoadjuvant settings
Charles Perou, USA
Overcoming resistance through genomically informed investigational cancer therapy?
Fabrice André, France
Clinical utility of genomic biomarkers in the adjuvant setting
Daniel F. Hayes, USA
Discussion